Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. [PDF]
Kuznik A +5 more
europepmc +1 more source
Potential of autophagy in subretinal fibrosis in neovascular age-related macular degeneration. [PDF]
Blasiak J +5 more
europepmc +1 more source
Real world outcomes of faricimab in treatment resistant neovascular age-related macular degeneration among Asian patients. [PDF]
Neo EZO +17 more
europepmc +1 more source
Deep-Learning-Based Analysis of Disease-Specific Structural Biomarkers on Retinal Sensitivity in Neovascular Age-Related Macular Degeneration. [PDF]
Reiter GS +8 more
europepmc +1 more source
AI-Based Retinal Image Analysis for the Detection of Choroidal Neovascular Age-Related Macular Degeneration (AMD) and Its Association with Brain Health. [PDF]
Shi C +10 more
europepmc +1 more source
Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration. [PDF]
Balser S +6 more
europepmc +1 more source
Real-World Efficacy and Durability of Faricimab in Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. [PDF]
Jeong A, Liang H, Baek SC, Sagong M.
europepmc +1 more source
Early Fluctuations of Exudative Lesions as Predictors of Two-Year Clinical Outcomes in Neovascular Age-Related Macular Degeneration. [PDF]
Pu J +7 more
europepmc +1 more source
Granzyme B contributes to subretinal fibrosis in neovascular age-related macular degeneration by modulating inflammation and epithelial-mesenchymal transition. [PDF]
Yoo HS +16 more
europepmc +1 more source

